Answers are grounded in this paper and cite their sources.
Real-world adherence and persistence to SGLT2 inhibitors is poor. Hence, targets for improving treatment adherence and persistence need to be identified and appropriate interventions implemented.
No takes yet. Share an insight, caveat, or question.
Ofori‐Asenso et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: